TEVA.TA Teva Pharmaceutical Industries Limited
Company Analysis
Latest News
🟢 Teva Pharmaceuticals is trading 4.04% up today after Moody’s upgrade to investment grade
Teva Pharmaceuticals is trading now 4.04% up at ILA 11080.00 after Moody’s Ratings upgraded its corporate credit rating to Baa3 from Ba1 with a stable...
🔴 Teva Pharmaceuticals is trading 4.1% down today on profit-taking after earnings-driven rally
Teva Pharmaceuticals is trading 4.1% down at ILA 10,430 as investors take profits following last week’s sharp earnings-driven rally. • Shares recently surged...
🔴 Teva Pharmaceuticals is trading 4.5% down today on profit-taking after recent gains
Teva Pharmaceuticals is trading 4.5% down at ILA 10,380 as investors lock in profits following a significant rally last week. • The stock recently surged...
Teva Beats Estimates and Raises Its Drug Outlook — But Can Branded Growth Outrun the Generics Decline?
Shares surged 10.5% to ₪10,590 on the Tel Aviv Stock Exchange as Teva Pharmaceutical delivered Q2 2026 results that cleared a low bar set by analysts expecting...
🟢 Teva Pharmaceuticals is trading 10.5% up today after beating Q2 2026 earnings estimates
Teva Pharmaceuticals is trading 10.5% up today at $10,590 after releasing better-than-expected Q2 2026 results and hosting its earnings conference call. • The...
🟢 Teva Pharmaceuticals is trading 4.1% up today after Q2 2026 earnings
Teva Pharmaceuticals is trading 4.1% up at $9,980 after releasing second-quarter 2026 financial results and holding a conference call on July 29, 2026. • The...
Teva Secures Global Rights for Ocrevus Biosimilar, Advancing Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd. and Polpharma Biologics have entered a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab). This...
Teva advances vitiligo drug to Phase 2b, citing 75% facial improvement
Teva Pharmaceutical Industries will advance its anti-IL-15 antibody, TEV-408, into a Phase 2b vitiligo study. The company expects to begin the trial in the...